Pathologic factors are poorly associated with local recurrence of vulvar cancer

Objective: To evaluate factors associated with an increased risk of local recurrence of squamous cell carcinoma (SCCA) of the vulva. Materials and Methods: Sixty-seven pathologic specimens of vulvar SCCA from 1991-2010 were retrospectively reviewed by a gynecologic pathologist. Medical records were reviewed for demographic, treatment, disease, and follow-up information. Risk of local recurrence was analyzed using Wilcoxon rank sum test and Fisher’s analysis. Recurrence-free survival (RFS) was calculated with the Log Rank test and Cox regression. Results: Stage distribution in the 67 patients was: four (6.0%) Stage IA, 48 (77.6%) Stage IB, three (4.5%) Stage II, 11 (16.4%) Stage III, and one (1.5%) Stage IV. Overall five-year survival was 84% and median RFS was 84.8 months. Thirty-seven percent of patients (25/67) presented with a local recurrence at their initial re-presentation after initial treatment, accounting for 92.6% of initial recurrences. Rates of local recurrence were lower in non-Caucasians (p = 0.047) and when carcinoma in situ was present at the margin (p = 0.03). RFS was not affected by stage (p = 0.60), lymph node status (p = 0.55), tumor size (p=0.45), or pathologic factors. In particular, tumor distance from the surgical margins as a continuous variable or at any cut-off was not associated with either risk of local recurrence or shortened recurrence- free survival; however, there was a trend between prolonged RFS with increasing disease-free pathologic margin (p = 0.09). Conclusion: Risk of local recurrence and RFS of vulvar SCCA following surgical excision were not affected significantly by most clinical or pathologic variables, including lymph node status, and disease-free margin size.

Vulvar neoplasm; Local neoplasm recurrence; Cancer-free margin; Surgical pathology.

[1] Siegel R., Ward E., Brawley O., Jemal A.: “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths”. CA Cancer J. Clin., 2011, 61, 212.

[2] Hacker N.F.: “Vulvar cancer”. In: Berek J.S., Hacker N.F.. (eds). Practical gynecologic oncology. Baltimore: Williams & Wilkins, 2000, 553.

[3] Homesley H.D., Bundy B.N., Sedlis A., Yordan E., Berek J.S., Jahshan A., et al.: “Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study)”. Am. J. Obstet. Gynecol., 1991, 164, 997.

[4] Woolderink J.M., de Bock G.H., de Hullu J.A., Davy M.J., van der Zee A.G., Mourits M.J.: “Patterns and frequency of recurrences of squamous cell carcinoma of the vulva”. Gynecol. Oncol., 2006, 103, 293.

[5] Gadducci A., Tana R., Barsotti C., Guerrieri M.E., Genazzani A.R.: “Clinico pathological and biological prognostic variables in squamous cell carcinoma of the vulva”. Crit. Rev. Oncol. Hematol., 2012, 83, 71.

[6] Gonzalez Bosquet J., Magrina J.F., Gaffey T.A., Hernandez J.L., Webb M.J., Cliby W.A., et al.: “Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva”. Gynecol. Oncol., 2005, 97, 828.

[7] Lataifeh I., Nascimento M.C., Nicklin J.L., Perrin L.C., Crandon A.J., Obermair A.: “Patterns of recurrence and disease-free survival in advanced squamous cell carcinoma of the vulva”. Gynecol. Oncol., 2004, 95, 701.

[8] Podratz K.C., Symmonds R.E., Taylor W.F.: “Carcinoma of the vulva: analysis of treatment failures”. Am. J. Obstet. Gynecol., 1982, 143, 340.

[9] Woelber L., Mahner S., Voelker K., Eulenburg C.Z., Gieseking F., Choschzick M., et al.: “Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer”. Anticancer Res., 2009, 29,

545.

[10] Raspagliesi F., Hanozet F., Ditto A., Solima E., Zanaboni F., Vecchione F., et al.: “Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva”. Gynecol. Oncol., 2006, 102, 333.

[11] Maggino T., Landoni F., Sartori E., Zola P., Gadducci A., Alessi C., et al.: “Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study”. Cancer, 2000, 89, 116.

[12] Tantipalakorn C., Robertson G., Marsden D.E., Gebski V., Hacker N.F.: “Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer”. Obstet. Gynecol., 2009, 113, 895.

[13] Iacoponi S., Zapardiel I., Diestro M.D., Hernandez A., De Santiago J.: “Prognostic factors associated with local recurrence in squamous cell carcinoma of the vulva”. J. Gynecol. Oncol., 2013, 24, 242.

[14] Viswanathan A.N., Pinto A.P., Schultz D., Berkowitz R., Crum C.P.: “Relationship of margin status and radiation dose to recurrence in postoperative vulvar carcinoma”. Gynecol. Oncol., 2013, 130, 545.

[15] Chan J.K., Sugiyama V., Pham H., Gu M., Rutgers J., Osann K., et al.: “Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis”. Gynecol. Oncol., 2007, 104, 636.

[16] Denny L., Quinn M., Hacker N.: “FIGO Cancer Report 2012”. Int. J. Gynaecol. Obstet., 2012, 119, S89.

[17] De Hullu J.A., Hollema H., Lolkema S., Boezen M., Boonstra H., Burger M.P., et al.: “Vulvar carcinoma. The price of less radical surgery”. Cancer, 2002, 95, 2331.

[18] Woelber L., Choschzick M., Eulenburg C., Hager M., Jaenicke F., Gieseking F., et al.: “Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva”. Ann. Surg. Oncol., 2011, 18, 3811.

[19] Palaia I., Bellati F., Calcagno M., Musella A., Perniola G., Panici P.B.: “Invasive vulvar carcinoma and the question of the surgical margin”. Int. J. Gynaecol. Obstet., 2011, 114, 120.

[20] Aragona A.M., Cuneo N.A., Soderini A.H., Alcoba E.B.: “An analysis of reported independent prognostic factors for survival in squamous cell carcinoma of the vulva: is tumor size significance being underrated?” Gynecol. Oncol., 2014, 132, 643.

[21] Preti M., Ronco G., Ghiringhello B., Micheletti L.: “Recurrent squamous cell carcinoma of the vulva: clinicopathologic determinants identifying low risk patients”. Cancer, 2000, 88, 1869.

[22] Groenen S.M., Timmers P.J., Burger C.W.: “Recurrence rate in vulvar carcinoma in relation to pathological margin distance”. Int. J. Gynaecol. Obstet., 2010, 20, 869.

[23] Heaps J.M., Fu Y.S., Montz F.J., Hacker N.F., Berek J.S.: “Surgicalpathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva”. Gynecol. Oncol., 1990, 38, 309.

[24] Ioffe Y.J., Erickson B.K., Foster K.E., Mutch D.G., Powell M.A., Thaker P.H., et al.: “Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins”. Gynecol. Oncol., 2013, 129, 528.

[25] Panici P.B., Tomao F., Domenici L., Giannini A., Giannarelli D., Palaia I., et al.: “Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review”. Gynecol. Oncol., 2015, 137, 373.

[26] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[27] Sznurkowski J.J., Milczek T., Emerich J.: “Prognostic factors and a value of 2009 FIGO staging system in vulvar cancer”. Arch. Gynecol. Obstet., 2013, 287, 1211.

[28] Rauh-Hain J.A., Clemmer J., Clark R.M., Bradford L.S., Growdon W.B., Goodman A., et al.: “Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time”. Am. J. Obstet. Gynecol., 2013, 209, 468e1.